46 results on '"Maarten J. Deenen"'
Search Results
2. Data from Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
- Author
-
Annemieke Cats, Jan H.M. Schellens, Cornelis J.A. Punt, Jos H. Beijnen, Paul H.M. Smits, Henk-Jan Guchelaar, Andrew Vincent, Anthonius de Boer, Valerie D. Doodeman, Artur M Burylo, Jolien Tol, and Maarten J. Deenen
- Abstract
Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide polymorphisms (SNP) and haplotypes on outcome of capecitabine.Experimental Design: Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab. The coding region of dihydropyrimidine dehydrogenase gene (DPYD) was sequenced in 45 cases with grade 3 or more capecitabine-related toxicity and in 100 randomly selected controls (cohort). Most discriminating (P < 0.1) or frequently occurring (>1%) nonsynonymous SNPs were analyzed in all 568 patients. SNPs and haplotypes were associated with toxicity, capecitabine dose modifications, and survival.Results: A total of 29 SNPs were detected in the case–cohort analysis, of which 8 were analyzed in all 568 patients. Of the patients polymorphic for DPYD IVS14+1G>A, 2846A>T, and 1236G>A, 71% (5 of 7), 63% (5 of 8), and 50% (14 of 28) developed grade 3 to 4 diarrhea, respectively, compared with 24% in the overall population. All patients polymorphic for IVS14+1G>A developed any grade 3 to 4 toxicity, including one possibly capecitabine-related death. Because of toxicity, a mean capecitabine dose reduction of 50% was applied in IVS14+1G>A and 25% in 2846A>T variant allele carriers. Patients were categorized into six haplotype groups: one predicted for reduced (10%), and two for increased risks (41% and 33%) for severe diarrhea. Individual SNPs were not associated with overall survival, whereas one haplotype was associated with overall survival [HR (95% CI) = 0.57 (0.35–0.95)].Conclusions: DPYD IVS14+1G>A and 2846A>T predict for severe toxicity to capecitabine, for which patients require dose reductions. Haplotypes assist in selecting patients at risk for toxicity to capecitabine. Clin Cancer Res; 17(10); 3455–68. ©2011 AACR.
- Published
- 2023
3. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan
- Author
-
Emma C. Hulshof, Maarten J. Deenen, Marga Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne-Marie Buunk, Elisa J. F. Houwink, Arne Risselada, Gerard A. P. J. M. Rongen, Ron H. N. van Schaik, Daan J. Touw, Jan van der Weide, Roos van Westrhenen, Vera H. M. Deneer, Henk-Jan Guchelaar, and Jesse J. Swen
- Subjects
Genetics ,Genetics (clinical) - Published
- 2023
4. A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
- Author
-
Rob ter Heine, Michel M. van den Heuvel, Berber Piet, Maarten J. Deenen, Anthonie J. van der Wekken, Lizza E. L. Hendriks, Sander Croes, Robin M. J. M. van Geel, Frank G. A. Jansman, Rogier C. Boshuizen, Eric J. F. Franssen, Arthur A. J. Smit, Daphne W. Dumoulin, Thijs H. Oude Munnink, Egbert F. Smit, Hieronymus J. Derijks, Cor H. van der Leest, Jeroen J. M. A. Hendrikx, Dirk J. A. R. Moes, Nikki de Rouw, and Pulmonary Medicine
- Subjects
Cancer Research ,All institutes and research themes of the Radboud University Medical Center ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Oncology ,SDG 3 - Good Health and Well-being ,NIVOLUMAB PLUS IPILIMUMAB ,Pharmacology (medical) ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,OPEN-LABEL ,POPULATION PHARMACOKINETICS ,PEMBROLIZUMAB - Abstract
Contains fulltext : 292912.pdf (Publisher’s version ) (Open Access) BACKGROUND: Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide. OBJECTIVE: We aimed to develop alternative dosing regimens to reduce drug expenses. METHODS: We developed alternative dosing regimens for the following monoclonal antibodies used for the treatment of lung cancer: amivantamab, atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and ramucirumab; and for the antibody-drug conjugate trastuzumab deruxtecan. The alternative dosing regimens were developed by means of modeling and simulation based on the population pharmacokinetic models developed by the license holders. They were based on weight bands and the administration of complete vials to limit drug wastage. The resulting dosing regimens were developed to comply with criteria used by regulatory authorities for in silico dose development. RESULTS: We found that alternative dosing regimens could result in cost savings that range from 11 to 28%, and lead to equivalent pharmacokinetic exposure with no relevant increases in variability in exposure. CONCLUSIONS: Dosing regimens based on weight bands and the use of complete vials to reduce drug wastage result in less expenses while maintaining equivalent exposure. The level of evidence of our proposal is the same as accepted by regulatory authorities for the approval of alternative dosing regimens of other monoclonal antibodies in oncology. The proposed alternative dosing regimens can, therefore, be directly implemented in clinical practice.
- Published
- 2023
5. Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
- Author
-
Emma C. Hulshof, Mirjam de With, Geert-Jan Creemers, Henk-Jan Guchelaar, Ron HJ. Mathijssen, Hans Gelderblom, and Maarten J. Deenen
- Subjects
Cancer Research ,Oncology - Published
- 2022
6. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
- Author
-
Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A.L.M. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Sander Bins, Anna M.J. Thijs, Marjan M.J. Laven, Anke M. Hövels, Saskia A.C. Luelmo, Danny Houtsma, Katerina Shulman, Howard L. McLeod, Ron H.N. van Schaik, Henk-Jan Guchelaar, Ron H.J. Mathijssen, Hans Gelderblom, Maarten J. Deenen, Clinical Chemistry, Medical Oncology, and Pharmacy
- Subjects
Genotyping ,Cancer Research ,Toxicity ,Genotype ,Irinotecan ,digestive system ,UDP-glucuronosyl transferase ,SDG 3 - Good Health and Well-being ,Oncology ,Pharmacogenetics ,Costs and Cost Analysis ,Humans ,Camptothecin ,Prospective Studies ,Glucuronosyltransferase ,UGT ,Febrile Neutropenia - Abstract
Aim: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan.Patients and methods: In this prospective, multicentre, non-randomised study, patients intended for treatment with irinotecan were pre-therapeutically genotyped for UGT1A1*28 and UGT1A1)93. Homozygous variant carriers (UGT1A1 poor metabolisers; PMs) received an initial 30% dose reduction. The primary endpoint was incidence of febrile neutropenia in the first two cycles of treatment. Toxicity in UGT1A1 PMs was compared to a historical cohort of UGT1A1 PMs treated with full dose therapy, and to UGT1A1 non-PMs treated with full dose therapy in the current study. Secondary endpoints were pharmacokinetics, feasi- bility, and costs.Results: Of the 350 evaluable patients, 31 (8.9%) patients were UGT1A1 PM and received a median 30% dose reduction. The incidence of febrile neutropenia in this group was 6.5% compared to 24% in historical UGT1A1 PMs (P = 0.04) and was comparable to the incidence in UGT1A1 non-PMs treated with full dose therapy. Systemic exposure of SN-38 of reduced dosing in UGT1A1 PMs was still slightly higher compared to a standard-dosed irinotecan patient cohort (difference: thorn 32%). Cost analysis showed that genotype-guided dosing was cost-saving with a cost reduction of V183 per patient.Conclusion: UGT1A1 genotype-guided dosing significantly reduces the incidence of febrile neutropenia in UGT1A1 PM patients treated with irinotecan, results in a therapeutically effec- tive systemic drug exposure, and is cost-saving. Therefore, UGT1A1 genotype-guided dosing of irinotecan should be considered standard of care in order to improve individual patient safety. (C) 2022 The Authors. Published by Elsevier Ltd.
- Published
- 2022
7. Palliative systemic therapy and oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with unresectable colorectal peritoneal metastases in a phase II trial (CRC-PIPAC-II)
- Author
-
Vincent Van De Vlasakker, Paulien Rauwerdink, Koen P. Rovers, Emma C.E. Wassenaar, Maarten J. Deenen, Joost Nederend, Clément J.R. Huysentruyt, Remond J.A. Fijneman, Erik J.R.J. van der Hoeven, Mihaela M. Raicu, Alexander Constantinides, Onno Kranenburg, Maartje Los, Geert-Jan M. Creemers, Pim W.A. Burger, René J. Wiezer, Simon W. Nienhuijs, Robin J. Lurvink, Djamila Boerma, and Ignace H.J.T. de Hingh
- Subjects
Oncology ,Surgery ,General Medicine - Published
- 2023
8. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan
- Author
-
Emma C, Hulshof, Maarten J, Deenen, Marga, Nijenhuis, Bianca, Soree, Nienke J, de Boer-Veger, Anne-Marie, Buunk, Elisa J F, Houwink, Arne, Risselada, Gerard A P J M, Rongen, Ron H N, van Schaik, Daan J, Touw, Jan, van der Weide, Roos, van Westrhenen, Vera H M, Deneer, Henk-Jan, Guchelaar, and Jesse J, Swen
- Abstract
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of the anti-cancer drug irinotecan to decrease the risk of severe toxicity, such as (febrile) neutropenia or diarrhoea. Uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1 encoded by the UGT1A1 gene) enzyme deficiency increases risk of irinotecan-induced toxicity. Gene variants leading to UGT1A1 enzyme deficiency (e.g. UGT1A1*6, *28 and *37) can be used to optimize an individual's starting dose thereby preventing carriers from toxicity. Homozygous or compound heterozygous carriers of these allele variants are defined as UGT1A1 poor metabolisers (PM). DPWG recommends a 70% starting dose in PM patients and no dose reduction in IM patients who start treatment with irinotecan. Based on the DPWG clinical implication score, UGT1A1 genotyping is considered "essential", indicating that UGT1A1 testing must be performed prior to initiating irinotecan treatment.
- Published
- 2022
9. RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers
- Author
-
Ignace H. J. T. de Hingh, Koen P. Rovers, Maarten J. Deenen, and Robin J. Lurvink
- Subjects
Gastrointestinal Tract Cancers ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Gastroenterology ,Oxaliplatin ,Oncology ,Internal medicine ,medicine ,Dose escalation ,business ,medicine.drug - Published
- 2021
10. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: A matched pair analysis
- Author
-
Didier Meulendijks, Anthonius de Boer, Lisanne N. van Merendonk, Annemieke Cats, Jan H.M. Schellens, Jos H. Beijnen, Maarten J. Deenen, and Linda M. Henricks
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,medicine.disease ,Capecitabine ,03 medical and health sciences ,Dihydropyrimidine dehydrogenase deficiency ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Toxicity ,Cohort ,medicine ,Dihydropyrimidine dehydrogenase ,DPYD ,Dosing ,business ,medicine.drug - Abstract
Carriers of the genetic DPYD*2A variant, resulting in dihydropyrimidine dehydrogenase deficiency, are at significantly increased risk of developing severe fluoropyrimidine-associated toxicity. Upfront DPYD*2A genotype-based dose reductions improve patient safety, but uncertainty exists whether this has a negative impact on treatment effectiveness. Therefore, our study investigated effectiveness and safety of DPYD*2A genotype-guided dosing. A cohort of 40 prospectively identified heterozygous DPYD*2A carriers, treated with a ~50% reduced fluoropyrimidine dose, was identified. For effectiveness analysis, a matched pair-analysis was performed in which for each DPYD*2A carrier a matched DPYD*2A wild-type patient was identified. Overall survival and progression-free survival were compared between the matched groups. The frequency of severe (grade ≥ 3) treatment-related toxicity was compared to 1] a cohort of 1606 wild-type patients treated with full dose and 2] a cohort of historical controls derived from literature, i.e. 86 DPYD*2A variant carriers who received a full fluoropyrimidine dose. For 37 out of 40 DPYD*2A carriers, a matched control could be identified. Compared to matched controls, reduced doses did not negatively affect overall survival (median 27 months versus 24 months, p = 0.47) nor progression-free survival (median 14 months versus 10 months, p = 0.54). Risk of severe fluoropyrimidine-related toxicity in DPYD*2A carriers treated with reduced dose was 18%, comparable to wild-type patients (23%, p = 0.57) and significantly lower than the risk of 77% in DPYD*2A carriers treated with full dose (p < 0.001). Our study is the first to show that DPYD*2A genotype-guided dosing appears to have no negative effect on effectiveness of fluoropyrimidine-based chemotherapy, while resulting in significantly improved patient safety.
- Published
- 2019
11. Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency
- Author
-
Geert-Jan Creemers, Jeroen F. Schouten, Maarten J. Deenen, Jeroen Willems, and Stefan J.W.J. Sanders
- Subjects
Oncology ,medicine.medical_specialty ,Pyrrolidines ,Dihydropyrimidine Dehydrogenase Deficiency ,Colorectal cancer ,medicine.medical_treatment ,Trifluridine ,law.invention ,Capecitabine ,chemistry.chemical_compound ,law ,Internal medicine ,medicine ,Dihydropyrimidine dehydrogenase ,Humans ,Tipiracil ,Chemotherapy ,Clinical pharmacology ,business.industry ,Rectal Neoplasms ,Gastroenterology ,medicine.disease ,chemistry ,Toxicity ,Colonic Neoplasms ,business ,Thymine ,medicine.drug - Abstract
Clinical Practice Points • Severe toxicity of the fluoropyrimidine drugs 5-fluorouracil (5-FU) and its oral prodrug capecitabine is associated with deficiency of the primary inactivating enzyme dihydropyrimidine dehydrogenase (DPD). • Pretreatment screening for DPD deficiency is applied followed by initial dose reduction in DPD-deficient patients in order to prevent severe toxicity Nonetheless, severe toxicity may still occur and therefore, new treatment options are highly warranted. • Trifluridine/tipiracil is a new anticancer drug that is registered for the treatment of metastatic colorectal cancer in patients who have been previously treated with, or have contraindications for 5-FU-based chemotherapy. Importantly, its metabolism is completely independent of DPD. • Thereby, trifluridine/tipiracil may offer a new treatment paradigm for the safe treatment of DPD-deficient metastatic colorectal cancer patients.
- Published
- 2021
12. Toward predicting CYP2D6-mediated variable drug response from
- Author
-
Maaike, van der Lee, William G, Allard, Rolf H A M, Vossen, Renée F, Baak-Pablo, Roberta, Menafra, Birgit A L M, Deiman, Maarten J, Deenen, Patrick, Neven, Inger, Johansson, Stefano, Gastaldello, Magnus, Ingelman-Sundberg, Henk-Jan, Guchelaar, Jesse J, Swen, and Seyed Yahya, Anvar
- Subjects
Tamoxifen ,Cytochrome P-450 CYP2D6 ,Genotype ,Pharmaceutical Preparations ,Humans ,Prospective Studies ,Alleles - Abstract
Pharmacogenomics is a key component of personalized medicine that promises safer and more effective drug treatment by individualizing drug choice and dose based on genetic profiles. In clinical practice, genetic biomarkers are used to categorize patients into *-alleles to predict CYP450 enzyme activity and adjust drug dosages accordingly. However, this approach leaves a large part of variability in drug response unexplained. Here, we present a proof-of-concept approach that uses continuous-scale (instead of categorical) assignments to predict enzyme activity. We used full
- Published
- 2020
13. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)
- Author
-
Koen P, Rovers, Emma C E, Wassenaar, Robin J, Lurvink, Geert-Jan M, Creemers, Jacobus W A, Burger, Maartje, Los, Clément J R, Huysentruyt, Gesina, van Lijnschoten, Joost, Nederend, Max J, Lahaye, Maarten J, Deenen, Marinus J, Wiezer, Simon W, Nienhuijs, Djamila, Boerma, and Ignace H J T, de Hingh
- Subjects
Aerosols ,Oxaliplatin ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Colorectal Neoplasms ,Peritoneal Neoplasms - Abstract
Despite its increasing use, pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) has never been prospectively investigated as a palliative monotherapy for colorectal peritoneal metastases in clinical trials. This trial aimed to assess the safety (primary aim) and antitumor activity (key secondary aim) of PIPAC-OX monotherapy in patients with unresectable colorectal peritoneal metastases.In this two-center, single-arm, phase II trial, patients with isolated unresectable colorectal peritoneal metastases in any line of palliative treatment underwent 6-weekly PIPAC-OX (92 mg/mTwenty enrolled patients underwent 59 (median 3, range 1-6) PIPAC-OX procedures. Major treatment-related adverse events occurred in 3 of 20 (15%) patients after 5 of 59 (8%) procedures (abdominal pain, intraperitoneal hemorrhage, iatrogenic pneumothorax, transient liver toxicity), including one possibly treatment-related death (sepsis of unknown origin). Minor treatment-related adverse events occurred in all patients after 57 of 59 (97%) procedures, the most common being abdominal pain (all patients after 88% of procedures) and nausea (65% of patients after 39% of procedures). Median hospital stay was 1 day (range 0-3). Response rates were 0% (radiological), 50% (biochemical), 56% (pathological), and 56% (ascites). Median progression-free and overall survival were 3.5 months (interquartile range [IQR] 2.5-5.7) and 8.0 months (IQR 6.3-12.6), respectively.In patients with unresectable colorectal peritoneal metastases undergoing PIPAC-OX monotherapy, some major adverse events occurred and minor adverse events were common. The clinical relevance of observed biochemical, pathological, and ascites responses remains to be determined, especially since radiological response was absent.
- Published
- 2020
14. P0048THE EFFECT OF GENOTYPING ON THE NUMBER OF PHARMACOTHERAPEUTIC GENE-DRUG INTERVENTIONS IN CKD3-5 PATIENTS
- Author
-
Maarten J. Deenen, Marieke Kerskes, Carien Van den Eijnde, Rene J. Grouls, Birgit A. L. M. Deiman, and Albert-Jan L.H.J. Aarnoudse
- Subjects
Drug ,Polypharmacy ,Transplantation ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Psychological intervention ,Pharmacogenomic Testing ,Pharmacotherapy ,CYP2B6 Gene ,Nephrology ,Internal medicine ,Medicine ,business ,Genotyping ,Pharmacogenetics ,media_common - Abstract
Background and Aims Most patients with CKD (Chronic Kidney Disease) 3-5 are polypharmacy patients (i.e. use of ≥5 drugs). As renal function is important for the clearance of many drugs, dose adjustment is often necessary and some drugs are even contra-indicated in patients with CKD. Many of these drugs are metabolized by cytochrome P450 (CYP-enzymes) in the liver. Several genetic mutations in these CYP enzymes are known to result in an altered metabolism capacity of drugs. Knowledge of the patients CYP450 genotype may thereby be of added value in reducing the incidence of supratherapeutic concentrations of drugs and reducing side effects, especially in this patient population with already reduced renal function. The aim of this study was to determine the added value of pharmacogenetic testing to the routine medication evaluation in polypharmacy patients with CKD3-5 disease, defined as the total number of pharmacotherapeutic interventions based on a relevant gene-drug interaction as assessed by the nephrologist and hospital pharmacist. Method This was a prospective single-centre study in adult polypharmacy patients with CKD3-5 disease not on dialysis who visited the outpatient clinic of the Catharina Hospital Eindhoven, the Netherlands. In each patient enrolled in the study we determined a pharmacogenetic profile consisting of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and VKORC1. A gene-drug interaction was considered as relevant based on the DPWG (Dutch Pharmacogenetics Working Group) guideline. Of all these according to the DPWG guideline relevant gene-drug interactions the treating nephrologist and hospital pharmacist assessed the clinical relevance and necessity of a pharmacotherapeutic intervention in the individual patient. Primary endpoint of the study was the total number of applied pharmacotherapeutic interventions based on a relevant gene-drug interaction. Results A total of 61 patients were enrolled. Median eGFR in the study population was 18 ml/min. Patients used a median (range) number of 12 (5-20) drugs. Genotyping resulted in a total of 172 altered phenotypes based on a pharmogenetic mutation. We observed a total of 66 gene-drug interactions, of which 56 were considered relevant and resulted in 26 applied pharmacotherapeutic interventions in 20 (32.8%) patients. These interventions consisted of 10 dose adjustments (38.5%), 7 drug stops (26.9%) and 9 drug changes (34.6%). Conclusion Pharmacogenetic testing leads to additional pharmacotherapeutic interventions based on relevant gene-drug interactions. This study shows that pharmacogenetic testing in CKD3-5 patients can be of added value to the routine medication evaluation, and may further optimize pharmacotherapy in this population.
- Published
- 2020
15. Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial
- Author
-
Robin J, Lurvink, Rudaba, Tajzai, Koen P, Rovers, Emma C E, Wassenaar, Dirk-Jan A R, Moes, Giulia, Pluimakers, Djamila, Boerma, Jacobus W A, Burger, Simon W, Nienhuijs, Ignace H J T, de Hingh, and Maarten J, Deenen
- Subjects
Aerosols ,Oxaliplatin ,Static Electricity ,Humans ,Colorectal Neoplasms ,Peritoneal Neoplasms - Abstract
Electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) is a palliative treatment for unresectable peritoneal metastases from various primary cancers. However, little is known about the systemic pharmacokinetics of oxaliplatin after ePIPAC.Twenty patients with unresectable colorectal peritoneal metastases were treated with repetitive ePIPAC monotherapy with oxaliplatin (92 mg/mFour patients received one ePIPAC, three patients received two ePIPAC, and thirteen patients received ≥ 3 ePIPAC. The population pharmacokinetic models adequately described the pharmacokinetics of oxaliplatin after ePIPAC. The plasma ultrafiltrate CSystemic exposure to oxaliplatin after ePIPAC seemed comparable to that after systemic chemotherapy, as described in other literature. Since this is an indirect comparison, future research should focus on the direct comparison between the systemic exposure to oxaliplatin after ePIPAC and after systemic chemotherapy.NCT03246321, Pre-results; ISRCTN89947480, Pre-results; NTR6603, Pre-results; EudraCT: 2017-000927-29, Pre-results.
- Published
- 2020
16. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases
- Author
-
Emma C. Hulshof, H-J Guchelaar, N. Caserta, Maarten J. Deenen, Stefan Böhringer, Robin J. Lurvink, Jesse J. Swen, I.H.J.T. de Hingh, T. van Wezel, and Hans Gelderblom
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Pharmacogenomic Variants ,Colorectal cancer ,Mitomycin ,Hyperthermic Intraperitoneal Chemotherapy ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Cytochrome P-450 Enzyme System ,Internal medicine ,Mitomycin C ,medicine ,Clinical endpoint ,NAD(P)H Dehydrogenase (Quinone) ,Humans ,In patient ,Alleles ,Peritoneal Neoplasms ,Aged ,Retrospective Studies ,Antibiotics, Antineoplastic ,HIPEC ,business.industry ,Carcinoma ,Wild type ,General Medicine ,Biomarker ,Cytoreduction Surgical Procedures ,Middle Aged ,medicine.disease ,Prognosis ,POR ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,NQO1 ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,Female ,business ,Colorectal Neoplasms ,Pharmacogenetics - Abstract
Introduction: Mitomycin C (MMC) is commonly used in patients with colorectal peritoneal metastases (CPM) treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). MMC requires metabolic activation prior to exert its cytotoxic effect of which the main activating enzymes are NQO1 and POR. However, not all patients are able to activate MMC for example due to polymorphisms in the genes encoding these enzymes. The aim of this study was to investigate the association of NQO1*2, NQO1*3, and POR*28 with the efficacy of CRS + HIPEC with MMC in patients with CPM.Method: A retrospective follow-up design was used to study genetic association in patients with histologically proven CPM treated with CRS + HIPEC with MMC with respect to peritoneal recurrence rate after 3 months (primary endpoint), after 6 months, disease-free survival and overall survival. Genetic polymorphisms NQO1*2, NQO1*3, and POR*28 were tested for association.Results: A total of 253 patients were included. In NQO1*3 carriers the peritoneal recurrence rate 3 and 6 months after HIPEC was significantly higher than in wild type patients, respectively 30.0% vs 3.8% (p = 0.009) and 40.0% vs 12.1% (p = 0.031). In line with these results, NQO1*3 was associated with a shorter disease-free survival (HR 2.04, 95% CI [1.03-4.03]). There was no significant association with overall survival (HR 1.42, 95% CI [0.66-3.07]).Conclusion: Carriership of the NQO1*3 allele is associated with worse peritoneal recurrence rate and disease-free survival. These results suggest that individualization of patients treated with CRS + HIPEC based upon pharmacogenetics may be beneficial. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
- Published
- 2019
17. A Proof of Principle Study of the Terminal Sterilization of Prefilled Syringes Using A Water Cascade Process
- Author
-
Maarten J. Deenen, Joost P.C.M. Van Doornmalen Gomez Hoyos, Anne J.A. Drost-Wijnne, Rene J. Grouls, Ralph A.C. Van Wezel, and Elementary Processes in Gas Discharges
- Subjects
Pharmacology ,prefilled syringe ,business.industry ,ready-to-administer ,sterilization ,Terminal Sterilization ,RM1-950 ,Pharmacy ,Sterilization (microbiology) ,compounding ,Proof of concept ,Medicine ,Pharmacology (medical) ,Therapeutics. Pharmacology ,HD9665-9675 ,business ,Process engineering ,Prefilled Syringe ,Pharmaceutical industry ,water cascade sterilization - Abstract
Background A new development in drug compounding is the production of ready-to-administer sterilized prefilled syringes. A challenge with these syringes is the method of terminal sterilization. There is no information available whether water cascade sterilization is a suitable method. We investigated the effect of this sterilization method on cyclic olefin (co)polymer (CCP/COC) syringes. Methods For two brands ten prefilled syringes were sterilized using water cascade sterilization. The closure integrity, stopper movement, weight, diameter and physical appearance were determined before and after sterilization. As sterility test, additional syringes were filled with tryptic soy broth (TSB) and sterilized. After fourteen days microbiological growth was determined. Results Closure integrity testing showed no dye penetration inside the syringe. Together with the results for weight this showed that closure integrity is guaranteed. No significant stopper movement, deviation in diameter or visual anomalies were observed. No microbiological growth in TSB was visible. Conclusions The results of this proof of principle study show that the physical and microbiological stability of the cyclic olefin (co)polymer syringes is guaranteed during sterilization using a water cascade sterilizer. These results do not rule out the necessity for further stability experiments (e. g. interaction with drug product) to further proof the concept.
- Published
- 2018
18. Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan
- Author
-
Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit ALM Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Marjan Laven, Saskia Luelmo, Ron H.N. van Schaik, Henk-jan Guchelaar, Ron H.J. Mathijssen, Hans Gelderblom, and Maarten J. Deenen
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.disease ,digestive system ,Pharmacokinetic analysis ,Irinotecan ,Internal medicine ,Pancreatic cancer ,Genotype ,Medicine ,SNP ,Dosing ,business ,medicine.drug - Abstract
3574 Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantly associated with increased systemic exposure of irinotecan’s active metabolite SN-38 and subsequently severe irinotecan-associated adverse-events (AEs) including (febrile) neutropenia and diarrhea. Severe AEs may lead to hospitalization, loss of quality of life, treatment delay and/or treatment discontinuation. Nonetheless, prospective genetic screening is not yet routinely performed. The aim of this study was to determine the safety and pharmacokinetics of UGT1A1 genotype-guided dosing of irinotecan in UGT1A1 poor metabolizers (PMs), i.e. UGT1A1 *28/*28 and/or UGT1A1*93/*93 individuals, in order to reduce the incidence of severe irinotecan-associated AEs. Methods: A prospective, multi-center, non-randomized study was conducted in patients intended to be treated with irinotecan at a dose of ≥ 180 mg/m2 or 450-600 mg flat dose. All patients were pre-therapeutically genotyped for UGT1A1*28 and UGT1A1*93. In UGT1A1 PMs, an initial 30% dose reduction in the first cycle was applied followed by further individual dose titration based on neutrophil count and clinical tolerability. The primary endpoint was the incidence of febrile neutropenia in the first 2 cycles of irinotecan treatment. UGT1A1 PMs were compared to 1] historical control patients, i.e. homozygous polymorphic patients treated with full dose therapy identified from systematic literature review and to 2] UGT1A1 non-PMs treated with standard dose therapy. In addition, systemic SN-38 exposure (AUC0-500h) of reduced dosing in the UGT1A1 PM cohort was compared to a standard dosed irinotecan patient cohort [doi: 10.1200/JCO.2000.18.1.195] by an independent T-test. Results: A total of 349 patients were pre-therapeutically genotyped and included for analysis. Thirty-one (8.9%) patients were UGT1A1 PM, in whom an initial median 30% dose reduction was applied. The incidence of febrile neutropenia in this group was 6.5% compared to 24% in historical controls (n = 50) (p = 0.042) and comparable with the incidence (4.1%; p = 0.632) in UGT1A1 non-PMs treated with full dose therapy. The systemic exposure of SN-38 of reduced dosing in UGT1A1 PMs (n = 17) was comparable to the systemic exposure of the standard dosed irinotecan patient cohort (n = 46) with a relative difference of +24% (p = 0.054) with a geometric mean (CV) of SN-38 AUC0-500h of 391 (43.7%) versus 298 (75.3%) ng*h/mL, respectively. Conclusions: UGT1A1 genotype-guided dosing significantly reduces the incidence of febrile neutropenia in UGT1A1 PM patients treated with irinotecan. In addition, systemic drug exposure remained adequate, despite the 30% dose reduction. Therefore, UGT1A1 genotype-guided dosing of irinotecan should be considered standard of care in order to improve the individual patient safety. Clinical trial information: Trial NL6270 (NTR6612).
- Published
- 2021
19. Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
- Author
-
Maarten J. Deenen, Ewoudt M W van de Garde, Bas J M Peters, Franz M.N.H. Schramel, and Christine Cramer van der Welle
- Subjects
Drug ,medicine.medical_specialty ,business.industry ,Total cost ,media_common.quotation_subject ,non-small cell lung cancer (NSCLC) ,Cancer ,Day care ,medicine.disease ,Quality of life ,Maintenance therapy ,Internal medicine ,Health care ,medicine ,business ,media_common - Abstract
Background: The Value-Based Health Care (VBHC) concept defines patient value as patient relevant outcomes divided by costs. The aim of the present study is to explore systemic treatment costs versus overall survival (OS) over years. Methods: All patients diagnosed (in 2008-2014) with stage IV NSCLC and treated with systemic treatment in five Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (mg) for every drug in the applied systemic cancer treatments up to death. These amounts were multiplied by Dutch unit costs (cost/mg) expressed in EUR 2018 to construct total drug costs per line of treatment per patient. Costs for day care visits were added, if applicable. Results: Data was collected from 983 patients. Figure 1 shows the mean total drug costs (split per line of treatment), median OS, and ratio between total costs and OS per year of diagnosis. The mean total drug costs per one year of survival ranged from €13.168 to €20.767 during the period under study. The use of maintenance therapy results in higher total drug costs in patients diagnosed in 2011 and 2012. Conclusion: This study shows that systemic treatment costs increase over time without survival improvements. Evaluating additional patient relevant outcomes such as quality of life will be helpful to better understand the added patient value of newer therapies in the future.
- Published
- 2019
20. Is vancomycin clearance really correlated with hemoglobin? Arguments that it's not
- Author
-
Maarten J, Deenen and Rob, Ter Heine
- Subjects
Hemoglobins ,Kinetics ,Vancomycin ,Sepsis ,Humans - Published
- 2019
21. Is vancomycin clearance really correlated with hemoglobin? Arguments that it's not
- Author
-
Maarten J. Deenen and Rob ter Heine
- Subjects
Pharmacology ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,business.industry ,Pharmacology toxicology ,Medicine ,Vancomycin ,Pharmacology (medical) ,General Medicine ,Hemoglobin ,business ,medicine.drug - Abstract
Item does not contain fulltext
- Published
- 2019
22. Rs895819 inMIR27Aimproves the predictive value ofDPYDvariants to identify patients at risk of severe fluoropyrimidine-associated toxicity
- Author
-
Jan H.M. Schellens, Ursula Amstutz, Didier Meulendijks, Anthonius de Boer, Linda M. Henricks, Maarten J. Deenen, Jos H. Beijnen, Annemieke Cats, Tanja K. Froehlich, and Carlo R. Largiadèr
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Biology ,Pharmacology ,Logistic regression ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Genotype ,medicine ,Dihydropyrimidine dehydrogenase ,DPYD ,Allele ,Prospective cohort study ,Allele frequency ,Genotyping - Abstract
The objective of this study was to determine whether genotyping of MIR27A polymorphisms rs895819A>G and rs11671784C>T can be used to improve the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity (FP-toxicity). Patients treated previously in a prospective study with fluoropyrimidine-based chemotherapy were genotyped for rs895819 and rs11671784, and DPYD c.2846A>T, c.1679T>G, c.1129-5923C>G and c.1601G>A. The predictive value of MIR27A variants for early-onset grade ≥3 FP-toxicity, alone or in combination with DPYD variants, was tested in multivariable logistic regression models. Random-effects meta-analysis was performed, including previously published data. A total of 1,592 patients were included. Allele frequencies of rs895819 and rs11671784 were 0.331 and 0.020, respectively. In DPYD wild-type patients, MIR27A variants did not affect risk of FP-toxicity (OR 1.3 for ≥1 variant MIR27A allele vs. none, 95% CI: 0.87-1.82, p = 0.228). In contrast, in patients carrying DPYD variants, the presence of ≥1 rs895819 variant allele was associated with increased risk of FP-toxicity (OR 4.9, 95% CI: 1.24-19.7, p = 0.023). Rs11671784 was not associated with FP-toxicity (OR 2.9, 95% CI: 0.47-18.0, p = 0.253). Patients carrying a DPYD variant and rs895819 were at increased risk of FP-toxicity compared to patients wild type for rs895819 and DPYD (OR 2.4, 95% CI: 1.27-4.37, p = 0.007), while patients with a DPYD variant but without a MIR27A variant were not (OR 0.3 95% CI: 0.06-1.17, p = 0.081). In meta-analysis, rs895819 remained significantly associated with FP-toxicity in DPYD variant allele carriers, OR 5.4 (95% CI: 1.83-15.7, p = 0.002). This study demonstrates the clinical validity of combined MIR27A/DPYD screening to identify patients at risk of severe FP-toxicity.
- Published
- 2016
23. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele
- Author
-
Bart A. W. Jacobs, Jan H.M. Schellens, Maarten J. Deenen, Erik van Werkhoven, Abidin Aliev, Didier Meulendijks, Dick Pluim, Annemieke Cats, and Jos H. Beijnen
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,biology ,medicine.medical_treatment ,Pharmacology ,medicine.disease ,Thymidylate synthase ,Gastroenterology ,Peripheral blood mononuclear cell ,Capecitabine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Toxicity ,Genotype ,biology.protein ,medicine ,Allele ,Febrile neutropenia ,medicine.drug - Abstract
The fluoropyrimidines act by inhibiting thymidylate synthase (TS). Recent studies have shown that patients' risk of severe fluoropyrimidine-associated toxicity is affected by polymorphisms in the 5′-untranslated region of TYMS, the gene encoding TS. A G>C substitution in the promoter enhancer region of TYMS, rs183205964 (known as the 2RC allele), markedly reduces TS activity in vitro, but its clinical relevance is unknown. We determined rs183205964 in 1605 patients previously enrolled in a prospective multicenter study. Associations between putative low TS expression genotypes (3RC/2RC, 2RG/2RC, and 2RC/2RC) and severe toxicity were investigated using univariable and multivariable logistic regression. Activity of TS and TYMS gene expression were determined in peripheral blood mononuclear cells (PBMCs) of a patient carrying genotype 2RC/2RC and of a control group of healthy individuals. Among 1,605 patients, 28 patients (1.7%) carried the 2RC allele. Twenty patients (1.2%) carried a risk-associated genotype (2RG/2RC, n=13; 3RC/2RC, n=6; and 2RC/2RC, n=1), the eight remaining patients had genotype 3RG/2RC. Early severe toxicity and toxicity-related hospitalization were significantly more frequent in risk-associated genotype carriers (OR 3.0, 95%CI 1.04-8.93, p=0.043 and OR 3.8, 95%CI 1.19-11.9, p=0.024, respectively, in multivariable analysis). The patient with genotype 2RC/2RC was hospitalized twice and had severe febrile neutropenia, diarrhea, and hand-foot syndrome. Baseline TS activity and gene expression in PBMCs of this patient, and a healthy individual with the 2RC allele, were found to be within the normal range. Our study suggests that patients carrying rs183205964 are at strongly increased risk of severe, potentially life-threatening, toxicity when treated with fluoropyrimidines. What's new? Fluoropyrimidines are among the most commonly used anticancer drugs. Fluoropyrimidines act by inhibiting thymidylate synthase, encoded by the gene TYMS. A G>C substitution in the promoter enhancer region of TYMS, rs183205964, has been shown to reduce TS activity in vitro, but its effect in patients is unknown. We determined the clinical relevance of this variant as a predictor of severe fluoropyrimidine-induced toxicity in a cohort of 1605 patients treated with fluoropyrimidine-based chemotherapy, and demonstrate for the first time that rs183205964 is associated with risk of early severe toxicity.
- Published
- 2015
24. 404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)
- Author
-
G. Le Teuff, J.-P. Pignon, Maarten J. Deenen, Robert B. Diasio, Julien Taieb, A. B. P. Van Kuilenburg, Nathalie Cozic, J-C Boyer, Claire Palles, Ulrich M. Zanger, M.-C. Etienne-Grimaldi, E. Gross, F. Thomas-Jean, M-A. Loriot, D. Meulendijks, Barbara A. Jennings, Valérie Boige, T. Marinaki, and Carlo R. Largiadèr
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Meta-analysis ,Toxicity ,Medicine ,DPYD ,Clinical significance ,Hematology ,Patient data ,business - Published
- 2020
25. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial
- Author
-
Esther van Meerten, Ruben A G van Eerden, Alexander Constantinides, Alexandra R. M. Brandt-Kerkhof, Femke M. de Man, Geert Jan Creemers, Stijn L.W. Koolen, Checca Bakkers, Onno Kranenburg, Eva V. E. Madsen, Maarten J. Deenen, Nadine L. de Boer, Ignace H. J. T. de Hingh, Ron H.J. Mathijssen, Marjolein Diepeveen, Rachida Bouamar, Jacobus W. A. Burger, Cornelis Verhoef, Koen P. Rovers, Surgery, Medical Oncology, and Pharmacy
- Subjects
Oncology ,medicine.medical_specialty ,Organoplatinum Compounds ,Bevacizumab ,Colorectal cancer ,Leucovorin ,colorectal cancer ,Irinotecan ,intraperitoneal chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Protocol ,Journal Article ,medicine ,Humans ,Multicenter Studies as Topic ,systemic chemotherapy ,Infusions, Parenteral ,030212 general & internal medicine ,Peritoneal Neoplasms ,Medicine(all) ,Clinical Trials, Phase I as Topic ,Performance status ,business.industry ,palliative treatment ,General Medicine ,medicine.disease ,Oxaliplatin ,dose-escalation study ,peritoneal metastases ,Research Design ,Conventional PCI ,Peritoneal Cancer Index ,Hyperthermic intraperitoneal chemotherapy ,Fluorouracil ,Colorectal Neoplasms ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
IntroductionCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard of care for patients with peritoneal metastases of colorectal origin with a low/moderate abdominal disease load. In case of a peritoneal cancer index (PCI) score >20, CRS-HIPEC is not considered to be beneficial. Patients with a PCI >20 are currently offered palliative systemic chemotherapy. Previous studies have shown that systemic chemotherapy is less effective against peritoneal metastases than it is against haematogenous spread of colorectal cancer. It is suggested that patients with peritoneal metastases may benefit from the addition of intraperitoneal chemotherapy to systemic chemotherapy. Aim of this study is to establish the maximum tolerated dose of intraperitoneal irinotecan, added to standard of care systemic therapy for colorectal cancer. Secondary endpoints are to determine the safety and feasibility of this treatment and to establish the pharmacokinetic profile of intraperitoneally administered irinotecan.Methods and analysisThis phase I, ‘3+3’ dose-escalation, study is performed in two Dutch tertiary referral centres. The study population consists of adult patients with extensive peritoneal metastases of colorectal origin who have a good performance status and no extra-abdominal metastases. According to standard work-up for CRS-HIPEC, patients will undergo a diagnostic laparoscopy to score the PCI. In case of a PCI >20, a peritoneal access port will be placed in the abdomen of the patient. Through this port we will administer intraperitoneal irinotecan, in combination with standard systemic treatment consisting of 5-fluorouracil/leucovorin with oxaliplatin and the targeted agent bevacizumab. Therapy consists of a maximum of 12 cycles 2-weekly.Ethics and disseminationThis study protocol is approved by a research medical ethics committee (Rotterdam, Netherlands) and the Dutch Competent Authority (CCMO, The Hague, Netherlands). The results of this trial will be submitted for publication in a peer-reviewed scientific journal.Trail registration numberNL6988 and NL2018-000479-33; Pre-results.
- Published
- 2019
26. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
- Author
-
Linda M, Henricks, Lisanne N, van Merendonk, Didier, Meulendijks, Maarten J, Deenen, Jos H, Beijnen, Anthonius, de Boer, Annemieke, Cats, and Jan H M, Schellens
- Subjects
Adult ,Aged, 80 and over ,Male ,Antimetabolites, Antineoplastic ,Dihydropyrimidine Dehydrogenase Deficiency ,Matched-Pair Analysis ,Middle Aged ,Polymorphism, Single Nucleotide ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Fluorouracil ,Capecitabine ,Dihydrouracil Dehydrogenase (NADP) ,Aged ,Retrospective Studies - Abstract
Carriers of the genetic DPYD*2A variant, resulting in dihydropyrimidine dehydrogenase deficiency, are at significantly increased risk of developing severe fluoropyrimidine-associated toxicity. Upfront DPYD*2A genotype-based dose reductions improve patient safety, but uncertainty exists whether this has a negative impact on treatment effectiveness. Therefore, our study investigated effectiveness and safety of DPYD*2A genotype-guided dosing. A cohort of 40 prospectively identified heterozygous DPYD*2A carriers, treated with a ~50% reduced fluoropyrimidine dose, was identified. For effectiveness analysis, a matched pair-analysis was performed in which for each DPYD*2A carrier a matched DPYD*2A wild-type patient was identified. Overall survival and progression-free survival were compared between the matched groups. The frequency of severe (grade ≥ 3) treatment-related toxicity was compared to 1] a cohort of 1606 wild-type patients treated with full dose and 2] a cohort of historical controls derived from literature, i.e. 86 DPYD*2A variant carriers who received a full fluoropyrimidine dose. For 37 out of 40 DPYD*2A carriers, a matched control could be identified. Compared to matched controls, reduced doses did not negatively affect overall survival (median 27 months versus 24 months, p = 0.47) nor progression-free survival (median 14 months versus 10 months, p = 0.54). Risk of severe fluoropyrimidine-related toxicity in DPYD*2A carriers treated with reduced dose was 18%, comparable to wild-type patients (23%, p = 0.57) and significantly lower than the risk of 77% in DPYD*2A carriers treated with full dose (p0.001). Our study is the first to show that DPYD*2A genotype-guided dosing appears to have no negative effect on effectiveness of fluoropyrimidine-based chemotherapy, while resulting in significantly improved patient safety.
- Published
- 2018
27. FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
- Author
-
Carlo R. Largiadèr, Fabienne Thomas, Jean-Christophe Boyer, Barbara A. Jennings, Michèle Boisdron-Celle, M.-C. Etienne-Grimaldi, Robert B. Diasio, G. Le Teuff, Julien Taieb, Valérie Boige, Maarten J. Deenen, Eva Gross, Didier Meulendijks, J.P. Pignon, Ulrich M. Zanger, Nathalie Cozic, Claire Palles, Anthony M. Marinaki, and Marie-Anne Loriot
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Advanced stage ,Stock options ,Hematology ,Patient data ,Capecitabine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Dose adjustment ,030220 oncology & carcinogenesis ,Internal medicine ,Meta-analysis ,medicine ,Dihydropyrimidine dehydrogenase ,DPYD ,business ,medicine.drug - Abstract
Background Despite decades of research, performance of DPYD genotyping to predict FP toxicity (tox) is poorly documented. GPCO-UNICANCER and RNPGx groups initiated the FUSAFE MA on individual patient data (IPD) to assess the prognostic value of consensual deleterious DPYD variants on grade (G) 4-5 FP tox. Methods Eligibility criteria included unbiased recruitment of Caucasian patients (pts) without FP dose adjustment based on DPD status. Main endpoint was 12 weeks hematological or digestive G4-5 tox. Age, sex, body mass index (BMI), advanced stage (M- vs M+), FP drug (5FU vs capecitabine), FP administration (bolus±continuous vs continuous alone or p.o.) and associated anticancer drugs (AAD) were collected. Multivariable logistic models were applied. Performance was assessed by AUC and diagnostic indices maximizing Youden index. Results From the 18 identified eligible studies (10230 pts), 14 were included (9030 pts), with complete IPD collected for 6403 pts (84% colorectal, 16% M+, 66% 5FU, 80% AAD). G4-5 tox prevalence was 8% (518 events). DPYD variants *2A, D949V, *13 and HapB3 were carried by 0.9%, 1.2%, 0.2% and 3.9% of pts, respectively. The clinical model (M1) retained age, sex, BMI, FP-administration, AAD. Adding variants *2A/D949V/*13 (at least one mutated allele) significantly (p Table . 569P Model AUC (area under the curve) Sensitivity Specificity Positive predictive value Negative predictive value M1 0.725 69.7% 65.4% 15.1% 96.1% M2 0.750 75.5% 62.8% 15.2% 96.7% M3 0.752 76.4% 61.9% 15.0% 96.8% Conclusions This is the largest MA on DPYD genotyping and toxicity. It shows the relevance of clinical variables and of the 3 consensual DPYD variants. Despite its association with tox, HapB3 does not improve the discriminant ability to identify pts at risk of G4-5 toxicity. Legal entity responsible for the study Centre Antoine Lacassagne, Nice, France (Dr Marie-Christine Etienne-Grimaldi, coordinator). Funding French Cancer Institute (INCa) funding (PHRC-K 14-193 FUSAFE) and French Ligue Nationale Contre le Cancer. Disclosure V. Boige: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self): Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Travel / Accommodation / Expenses: Roche Genentech; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Prestizia; Advisory / Consultancy: Eisai; Travel / Accommodation / Expenses: Sanofi. J. Taieb: Advisory / Consultancy: Amgen; Advisory / Consultancy: Lily; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche; Advisory / Consultancy: Merck; Advisory / Consultancy: MSD; Advisory / Consultancy: Celgene; Advisory / Consultancy: Servier; Advisory / Consultancy: Sirtex; Advisory / Consultancy: Pierre Fabre. D. Meulendijks: Full / Part-time employment: AstraZeneca UK. C. Palles: Advisory / Consultancy: Oxford Cancer Biomarkers. U. Zanger: Licensing / Royalties: Robert Bosch GmbH. M. Boisdron-Celle: Speaker Bureau / Expert testimony, Leadership role, Shareholder / Stockholder / Stock options, Licensing / Royalties, Officer / Board of Directors: ODPM. A. Marinaki: Full / Part-time employment: Viapath. E. Gross: Licensing / Royalties: Klinikum Rechts der Isar der Technischen Universitat Munchen. All other authors have declared no conflicts of interest.
- Published
- 2019
28. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage
- Author
-
André J. A. M. van der Ven, David M. Burger, Clara T. M. M. de Kanter, Hanneke W. H. A. Fleuren, Peter P. Koopmans, Elizabeth H. Gisolf, Karin J. T. Grintjes-Huisman, Joost P.H. Drenth, Maarten J. Deenen, and Anthonius S. M. Dofferhoff
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Hepatitis C virus ,Human immunodeficiency virus (HIV) ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,HIV Infections ,medicine.disease_cause ,Gastroenterology ,Antiviral Agents ,Polyethylene Glycols ,Virological response ,Cohort Studies ,chemistry.chemical_compound ,Internal medicine ,Ribavirin ,Medicine ,Humans ,Pharmacology (medical) ,Chromatography, High Pressure Liquid ,Retrospective Studies ,Pharmacology ,Dose-Response Relationship, Drug ,business.industry ,Coinfection ,virus diseases ,Retrospective cohort study ,Hepatitis C, Chronic ,Middle Aged ,Increased risk ,Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,chemistry ,Cohort ,Immunology ,Plasma concentration ,Drug Therapy, Combination ,Female ,Interferons ,business - Abstract
Item does not contain fulltext BACKGROUND: Hepatitis C virus (HCV)/HIV-coinfected patients respond worse to dual therapy with ribavirin (RBV)/peginterferon compared with HCV-monoinfected patients. Several trials found that lower RBV plasma concentrations are associated with impaired virological response rates. The aim of this study was to determine RBV plasma concentrations in a cohort of HCV-monoinfected and HCV/HIV-coinfected patients. Our hypothesis is that HCV/HIV-coinfected patients have lower RBV plasma concentrations, which may in part explain their inferior response to dual therapy. METHODS: A retrospective cohort study was performed in chronic HCV-monoinfected and HCV/HIV-coinfected patients who received peginterferon and weight-based RBV. Plasma RBV concentrations were determined at weeks 4 and 12 by a validated high-performance liquid chromatography assay. RBV concentrations were compared between monoinfected and coinfected patients. We calculated the proportion of patients with a subtherapeutic RBV plasma concentration defined as
- Published
- 2015
29. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC)
- Author
-
Marinus J. Wiezer, Anna M.J. Thijs, Iris van 't Erve, Alexander Constantinides, Clément J. Huysentruyt, Ignace H. J. T. de Hingh, Simon W. Nienhuijs, Djamila Boerma, Koen P. Rovers, Onno Kranenburg, Harm J. Scholten, Rudaba Tajzai, Maarten J. Deenen, Emma C. E. Wassenaar, Geert Jan Creemers, J. Nederend, Thomas J.M. Kootstra, Jacobus W. A. Burger, Remond J.Sa. Fijneman, Max J. Lahaye, Maartje Los, Robin J. Lurvink, Signal Processing Systems, Center for Care & Cure Technology Eindhoven, Epidemiologie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
PHARMACOKINETICS ,Colorectal cancer ,CARCINOMATOSIS ,Phases of clinical research ,SDG 3 – Goede gezondheid en welzijn ,0302 clinical medicine ,QUALITY-OF-LIFE ,Protocol ,Multicenter Studies as Topic ,Medicine ,Peritoneal Neoplasms ,Netherlands ,Medicine(all) ,Body surface area ,Palliative Care ,Common Terminology Criteria for Adverse Events ,General Medicine ,CANCER ,Colorectal surgery ,Oxaliplatin ,peritoneal metastases ,Oncology ,Tolerability ,SAFETY ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,medicine.drug ,medicine.medical_specialty ,Static Electricity ,QUESTIONNAIRE ,PIPAC ,Antineoplastic Agents ,colorectal cancer ,intraperitoneal chemotherapy ,CLASSIFICATION ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,SDG 3 - Good Health and Well-being ,Internal medicine ,Humans ,Aerosols ,Performance status ,business.industry ,Nebulizers and Vaporizers ,medicine.disease ,gastrointestinal tumours ,1ST EVIDENCE ,INTRAABDOMINAL PRESSURE ,colorectal surgery ,PENETRATION ,business ,Pneumoperitoneum, Artificial - Abstract
IntroductionRepetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is known about its feasibility, safety, tolerability, efficacy, costs and pharmacokinetics in this setting. This study aims to explore these parameters in patients with isolated unresectable colorectal PM who receive repetitive ePIPAC-OX as a palliative monotherapy.Methods and analysisThis multicentre, open-label, single-arm, phase II study is performed in two Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal carcinoma, a good performance status, adequate organ functions and no symptoms of gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled ePIPAC-OX (92 mg/m2body surface area (BSA)) with intravenous leucovorin (20 mg/m2BSA) and bolus 5-fluorouracil (400 mg/m2BSA) every 6 weeks. Four weeks after each procedure, patients undergo clinical, radiological and biochemical evaluation. ePIPAC-OX is repeated until disease progression, after which standard palliative treatment is (re)considered. The primary outcome is the number of patients with major toxicity (grade ≥3 according to the Common Terminology Criteria for Adverse Events v4.0) up to 4 weeks after the last ePIPAC-OX. Secondary outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, minor toxicity, postoperative complications, hospital stay, readmissions, quality of life, costs, pharmacokinetics of oxaliplatin, progression-free survival, overall survival, and the radiological, histopathological, cytological, biochemical and macroscopic tumour response.Ethics and disseminationThis study is approved by an ethics committee, the Dutch competent authority and the institutional review boards of both study centres. Results are intended for publication in peer-reviewed medical journals and for presentation to patients, healthcare professionals and other stakeholders.Trial registration numberNCT03246321, Pre-results;ISRCTN89947480, Pre-results; NTR6603, Pre-results; EudraCT: 2017-000927-29, Pre-results.
- Published
- 2019
30. Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism
- Author
-
Maarten J. Deenen, Jos H. Beijnen, Jan H.M. Schellens, and Annemieke Cats
- Subjects
Drug ,Cancer Research ,Polymorphism, Genetic ,Methyltransferase ,business.industry ,media_common.quotation_subject ,Genetic Variation ,Antineoplastic Agents ,Biology ,Pharmacology ,Oncology ,Pharmacogenetics ,Neoplasms ,Pharmacodynamics ,Genetic variation ,Humans ,Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy ,Personalized medicine ,Genetic variability ,business ,Drug metabolism ,media_common - Abstract
Learning Objectives After completing this course, the reader will be able to: Identify genetic variants of glutathione S-transferase and uridine diphosphoglucuronosyl transferase that have been shown to affect clinical outcomes in patients with cancer and describe the general effects of these variants with respect to standard treatment.Describe potential treatment considerations in patients with cancer who have genetic polymorphisms that affect Phase II metabolism of anticancer drugs. CME This article is available for continuing medical education credit at CME.TheOncologist.com Equivalent drug doses may lead to wide interpatient variability in drug response to anticancer therapy. Known determinants that may affect the pharmacological response to a drug are, among others, nongenetic factors, including age, gender, use of comedication, and liver and renal function. Nonetheless, these covariates do not explain all the observed interpatient variability. Differences in genetic constitution among patients have been identified to be important factors that contribute to differences in drug response. Because genetic polymorphism may affect the expression and activity of proteins encoded, it is a key covariate that is responsible for variability in drug metabolism, drug transport, and pharmacodynamic drug effects. We present a series of four reviews about pharmacogenetic variability. This third part in the series of reviews is focused on genetic variability in phase II drug-metabolizing enzymes (glutathione S-transferases, uridine diphosphoglucuronosyl transferases, methyltransferases, sulfotransferases, and N-acetyltransferases) and discusses the effects of genetic polymorphism within the genes encoding these enzymes on anticancer drug therapy outcome. Based on the literature reviewed, opportunities for patient-tailored anticancer therapy are proposed.
- Published
- 2011
31. Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects
- Author
-
Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, and Maarten J. Deenen
- Subjects
Drug ,Cancer Research ,Candidate gene ,Polymorphism, Genetic ,business.industry ,media_common.quotation_subject ,Genetic Variation ,Antineoplastic Agents ,Pharmacology ,medicine.disease_cause ,Oncology ,Neoplasms ,Genetic variation ,medicine ,Humans ,Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy ,KRAS ,Genetic variability ,Personalized medicine ,business ,Drug metabolism ,Pharmacogenetics ,media_common - Abstract
Learning Objectives After completing this course, the reader will be able to: Identify genetic polymorphisms within pharmacodynamic candidate genes that are potential predictive markers for treatment outcome with anticancer drugs.Describe treatment selection considerations in patients with cancer who have genetic polymorphisms that could influence pharmacodynamic aspects of anticancer therapy. CME This article is available for continuing medical education credit at CME.TheOncologist.com Response to treatment with anticancer drugs is subject to wide interindividual variability. This variability is expressed not only as differences in severity and type of toxicity, but also as differences in effectiveness. Variability in the constitution of genes involved in the pharmacokinetic and pharmacodynamic pathways of anticancer drugs has been shown to possibly translate into differences in treatment outcome. The overall knowledge in the field of pharmacogenetics has tremendously increased over the last couple of years, and has thereby provided opportunities for patient-tailored anticancer therapy. In previous parts of this series, we described pharmacogenetic variability in anticancer phase I and phase II drug metabolism and drug transport. This fourth part of a four-part series of reviews is focused on pharmacodynamic variability and encompasses genetic variation in drug target genes such as those encoding thymidylate synthase, methylene tetrahydrofolate reductase, and ribonucleotide reductase. Furthermore, genetic variability in other pharmacodynamic candidate genes involved in response to anticancer drugs is discussed, including genes involved in DNA repair such as those encoding excision repair crosscomplementing group 1 and group 2, x-ray crosscomplementing group 1 and group 3, and breast cancer genes 1 and 2. Finally, somatic mutations in KRAS and the gene encoding epidermal growth factor receptor (EGFR) and implications for EGFR-targeted drugs are discussed. Potential implications and opportunities for patient and drug selection for genotype-driven anticancer therapy are outlined.
- Published
- 2011
32. Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism
- Author
-
Jos H. Beijnen, Maarten J. Deenen, Annemieke Cats, and Jan H.M. Schellens
- Subjects
Drug ,Cancer Research ,CYP2D6 ,ATP Binding Cassette Transporter, Subfamily B ,Genotype ,media_common.quotation_subject ,Antineoplastic Agents ,Pharmacology ,Polymorphism, Single Nucleotide ,Pharmacokinetics ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Humans ,Medicine ,Clinical Pharmacology: Pharmacogenetics: Opportunities for Patient-Tailored Anticancer Therapy ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Enzyme Inhibitors ,Precision Medicine ,Randomized Controlled Trials as Topic ,media_common ,Dose-Response Relationship, Drug ,business.industry ,Neoplasm Proteins ,Treatment Outcome ,Oncology ,Pharmacogenetics ,Pharmacodynamics ,ATP-Binding Cassette Transporters ,DPYD ,Aryl Hydrocarbon Hydroxylases ,Personalized medicine ,business ,Biomarkers ,Drug metabolism - Abstract
Learning Objectives After completing this course, the reader will be able to: List currently identified candidate genes involved in phase I metabolism that are potential pharmacogenetic markers in anticancer therapy.Describe the general effect on standard treatment of allelic variants of the candidate genes and the implications for individualized treatment. This article is available for continuing medical education credit at CME.TheOncologist.com Equivalent drug doses in anticancer chemotherapy may lead to wide interpatient variability in drug response reflected by differences in treatment response or in severity of adverse drug reactions. Differences in the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of a drug contribute to variation in treatment outcome among patients. An important factor responsible for this variability is genetic polymorphism in genes that are involved in PK/PD processes, including drug transporters, phase I and II metabolizing enzymes, and drug targets, and other genes that interfere with drug response. In order to achieve personalized pharmacotherapy, drug dosing and treatment selection based on genotype might help to increase treatment efficacy while reducing unnecessary toxicity. We present a series of four reviews about pharmacogenetic variability in anticancer drug treatment. This is the second review in the series and is focused on genetic variability in genes encoding drug transporters (ABCB1 and ABCG2) and phase I drug-metabolizing enzymes (CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, CDA and BLMH) and their associations with anticancer drug treatment outcome. Based on the literature reviewed, opportunities for patient-tailored anticancer therapy are presented.
- Published
- 2011
33. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity
- Author
-
Didier, Meulendijks, Linda M, Henricks, Ursula, Amstutz, Tanja K, Froehlich, Carlo R, Largiadèr, Jos H, Beijnen, Anthonius, de Boer, Maarten J, Deenen, Annemieke, Cats, and Jan H M, Schellens
- Subjects
Adult ,Aged, 80 and over ,Male ,Risk ,Genotype ,Middle Aged ,Polymorphism, Single Nucleotide ,MicroRNAs ,Gene Frequency ,Humans ,Female ,Fluorouracil ,Colorectal Neoplasms ,Dihydrouracil Dehydrogenase (NADP) ,Genetic Association Studies ,Aged - Abstract
The objective of this study was to determine whether genotyping of MIR27A polymorphisms rs895819AG and rs11671784CT can be used to improve the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity (FP-toxicity). Patients treated previously in a prospective study with fluoropyrimidine-based chemotherapy were genotyped for rs895819 and rs11671784, and DPYD c.2846AT, c.1679TG, c.1129-5923CG and c.1601GA. The predictive value of MIR27A variants for early-onset grade ≥3 FP-toxicity, alone or in combination with DPYD variants, was tested in multivariable logistic regression models. Random-effects meta-analysis was performed, including previously published data. A total of 1,592 patients were included. Allele frequencies of rs895819 and rs11671784 were 0.331 and 0.020, respectively. In DPYD wild-type patients, MIR27A variants did not affect risk of FP-toxicity (OR 1.3 for ≥1 variant MIR27A allele vs. none, 95% CI: 0.87-1.82, p = 0.228). In contrast, in patients carrying DPYD variants, the presence of ≥1 rs895819 variant allele was associated with increased risk of FP-toxicity (OR 4.9, 95% CI: 1.24-19.7, p = 0.023). Rs11671784 was not associated with FP-toxicity (OR 2.9, 95% CI: 0.47-18.0, p = 0.253). Patients carrying a DPYD variant and rs895819 were at increased risk of FP-toxicity compared to patients wild type for rs895819 and DPYD (OR 2.4, 95% CI: 1.27-4.37, p = 0.007), while patients with a DPYD variant but without a MIR27A variant were not (OR 0.3 95% CI: 0.06-1.17, p = 0.081). In meta-analysis, rs895819 remained significantly associated with FP-toxicity in DPYD variant allele carriers, OR 5.4 (95% CI: 1.83-15.7, p = 0.002). This study demonstrates the clinical validity of combined MIR27A/DPYD screening to identify patients at risk of severe FP-toxicity.
- Published
- 2015
34. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction
- Author
-
Maarten J. Deenen, Henk Boot, Annemieke Cats, Marie-Cecile Legdeur, Didier Meulendijks, Jan H.M. Schellens, and Jos H. Beijnen
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Cancer Research ,Esophageal Neoplasms ,Organoplatinum Compounds ,Nausea ,Metabolic Clearance Rate ,Docetaxel ,Neutropenia ,Toxicology ,Polymorphism, Single Nucleotide ,Disease-Free Survival ,Capecitabine ,Leukocytopenia ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacokinetics ,Pharmacology (medical) ,Genetic Predisposition to Disease ,Fatigue ,Aged ,Pharmacology ,business.industry ,Alopecia ,Middle Aged ,medicine.disease ,Oxaliplatin ,Regimen ,Treatment Outcome ,Pharmacogenetics ,Area Under Curve ,Female ,Taxoids ,Esophagogastric Junction ,medicine.symptom ,business ,Gastric cancer ,Febrile neutropenia ,medicine.drug - Abstract
Purpose: The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advanced cancer of the stomach or the gastroesophageal junction (GEJ). Secondary objectives included pharmacokinetic and pharmacogenetic analyses. Methods: Patients were treated in escalating dose levels with docetaxel and oxaliplatin (both on day 1), plus capecitabine b.i.d. on days 1-14 every 3 weeks, to determine the dose-limiting toxicity and maximum tolerated dose (MTD). An expansion cohort was treated at the MTD. A total of ten polymorphisms in pharmacokinetic and pharmacodynamic candidate genes were analyzed and tested for association with treatment outcome. Results: A total of 34 evaluable patients were enrolled. The MTD was docetaxel 50 mg/m2, oxaliplatin 100 mg/m2 plus capecitabine 850 mg/m2 b.i.d. The median number of treatment cycles was 6 (range 2-8). Grade ≤ 3 toxicities included neutropenia (24 %), leukocytopenia (15 %), febrile neutropenia (12 %), fatigue (9 %) and diarrhea (6 %). The overall response rate was 45 %; two patients achieved a complete response. Median progression-free survival and overall survival were 6.5 months (95 % CI 5.4-7.6) and 11.0 months (95 % CI 7.9-14.1), respectively. The polymorphisms ERCC1 354C>T, TYMS 1053C>T and rs2612091 in ENOSF1 were associated with severe toxicity; ERCC1 354C>T and ERCC2 2251A>C were associated with poor progression-free survival. Conclusion: Docetaxel, oxaliplatin plus capecitabine are a well-tolerable, safe and effective treatment regimen for patients with advanced cancer of the stomach or GEJ. Pharmacogenetic markers in pharmacokinetic and pharmacodynamic candidate genes may be predictive for treatment outcome.
- Published
- 2015
35. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
- Author
-
Jos H. Beijnen, Maarten J. Deenen, Artur M. Burylo, Dick Pluim, Didier Meulendijks, Anneloes E M Ruijter, Jan H.M. Schellens, Robin M.J.M. van Geel, and Bart A. W. Jacobs
- Subjects
Chemistry ,Clinical Biochemistry ,General Medicine ,Peripheral blood mononuclear cell ,Molecular biology ,High-performance liquid chromatography ,Dihydropyrimidine dehydrogenase activity ,Sample stability ,Analytical Chemistry ,Medical Laboratory Technology ,Biochemistry ,Pharmacodynamics ,Dihydropyrimidine dehydrogenase ,Leukocytes, Mononuclear ,Humans ,In patient ,Hemoglobin ,General Pharmacology, Toxicology and Pharmaceutics ,Chromatography, High Pressure Liquid ,Dihydrouracil Dehydrogenase (NADP) - Abstract
Background: Dihydropyrimidine dehydrogenase (DPD) activity determination in peripheral blood mononuclear cells of DPD deficient patients was hitherto inaccurate due to hemoglobin (Hb) contamination. We developed an improved method for accurate measurement of DPD activity in patients. Results: DPD activity was determined by HPLC with online radioisotope detection using liquid scintillation counting. Hb was determined spectrophotometrically. Method accuracy and precision were significantly improved by using cumulative area of all peaks as IS. Peripheral blood mononuclear cell lysates from DPD deficient patients were highly contaminated with on average 23.3% (range 2.7–51%) of Hb resulting in up to twofold underestimated DPD activity. DPD activities were corrected for Hb contamination. The method was validated and showed good long-term sample stability. Conclusion: This method has increased specificity allowing accurate identification of DPD deficient patients.
- Published
- 2015
36. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele
- Author
-
Didier, Meulendijks, Bart A W, Jacobs, Abidin, Aliev, Dick, Pluim, Erik, van Werkhoven, Maarten J, Deenen, Jos H, Beijnen, Annemieke, Cats, and Jan H M, Schellens
- Subjects
Adult ,Aged, 80 and over ,Male ,Antimetabolites, Antineoplastic ,Genotype ,Gene Expression ,Thymidylate Synthase ,Middle Aged ,Polymorphism, Single Nucleotide ,Young Adult ,Pyrimidines ,Drug Resistance, Neoplasm ,Tandem Repeat Sequences ,Case-Control Studies ,Leukocytes, Mononuclear ,Humans ,Female ,Fluorouracil ,5' Untranslated Regions ,Alleles ,Aged - Abstract
The fluoropyrimidines act by inhibiting thymidylate synthase (TS). Recent studies have shown that patients' risk of severe fluoropyrimidine-associated toxicity is affected by polymorphisms in the 5'-untranslated region of TYMS, the gene encoding TS. A GC substitution in the promoter enhancer region of TYMS, rs183205964 (known as the 2RC allele), markedly reduces TS activity in vitro, but its clinical relevance is unknown. We determined rs183205964 in 1605 patients previously enrolled in a prospective multicenter study. Associations between putative low TS expression genotypes (3RC/2RC, 2RG/2RC, and 2RC/2RC) and severe toxicity were investigated using univariable and multivariable logistic regression. Activity of TS and TYMS gene expression were determined in peripheral blood mononuclear cells (PBMCs) of a patient carrying genotype 2RC/2RC and of a control group of healthy individuals. Among 1,605 patients, 28 patients (1.7%) carried the 2RC allele. Twenty patients (1.2%) carried a risk-associated genotype (2RG/2RC, n=13; 3RC/2RC, n=6; and 2RC/2RC, n=1), the eight remaining patients had genotype 3RG/2RC. Early severe toxicity and toxicity-related hospitalization were significantly more frequent in risk-associated genotype carriers (OR 3.0, 95%CI 1.04-8.93, p=0.043 and OR 3.8, 95%CI 1.19-11.9, p=0.024, respectively, in multivariable analysis). The patient with genotype 2RC/2RC was hospitalized twice and had severe febrile neutropenia, diarrhea, and hand-foot syndrome. Baseline TS activity and gene expression in PBMCs of this patient, and a healthy individual with the 2RC allele, were found to be within the normal range. Our study suggests that patients carrying rs183205964 are at strongly increased risk of severe, potentially life-threatening, toxicity when treated with fluoropyrimidines.
- Published
- 2015
37. Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
- Author
-
Annemieke Cats, Maarten J. Deenen, Jan H.M. Schellens, and Jos H. Beijnen
- Subjects
business.industry ,Tegafur/uracil ,Uracil ,Pharmacology ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Tegafur ,lcsh:RC254-282 ,Capecitabine ,chemistry.chemical_compound ,Oncology ,chemistry ,Pharmacokinetics ,Dihydropyrimidine dehydrogenase ,Medicine ,DPYD ,business ,Sorivudine ,Letters to the Editor ,medicine.drug - Abstract
To the editor, With interest we read the article by Dr Cubero and colleagues, in which they evaluated the safety of tegafur-uracil (UFT®) in five cases with partial dihydropyrimidine dehydrogenase (DPD) deficiency [Cubero et al. 2012]. Based on our previous experience [Deenen et al. 2010], however, we would like to express our concern about their conclusion that UFT is a safe alternative for the treatment of patients with partial DPD deficiency. Cubero and colleagues make the erroneous and unproven statement that the presence of uracil in UFT creates an artificial DPD deficiency, and that the DPD activity in patients with normal DPD activity would then be similarly as low as in DPD-deficient patients. This assumption, however, is incorrect. As uracil is a competitive inhibitor of DPD, it competes with 5-fluorouracil (5-FU) for DPD-mediated metabolism. This does not mean that the activity of DPD is depleted, as suggested by Cubero and colleagues, in contrast, its activity is fully utilized, as well as for the metabolism of uracil, as for the metabolism of 5-FU. We would like to caution that treating patients with partial DPD deficiency with the standard dose of UFT may unnecessarily lead to severe, potentially lethal toxicity. Unlike the cases described by Cubero and colleagues, we could previously describe four cases presenting with comparable severe toxicity profiles upon treatment with UFT as had previously occurred during treatment with capecitabine or 5-FU. In all subjects an underlying partial DPD deficiency was identified by genotype and phenotype analyses [Deenen et al. 2010]. Furthermore, there are several pharmacological lines of argument that support our clinical observation, i.e. that the standard dose of UFT is not safe in (partial) DPD-deficient patients. First, pharmacokinetic studies have shown that DPD remains essential for the metabolism of UFT, with significantly longer half-lives of 5-FU after administration of UFT compared with 5-FU administered intravenously [Ho et al. 1998]. This is due to the presence of uracil in UFT. Since DPD-deficient patients already have longer half-lives of 5-FU than other patients [Mattison et al. 2006], presence of uracil increases its half-life even further. This in turn leads to prolonged and elevated circulating levels of 5-FU, with a subsequently increased risk of 5-FU-induced severe toxicity. Another argument underscoring the importance of normal DPD function in the safe application of UFT, is the experience with S-1. S-1 is another drug combination of tegafur, consisting of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate in a molar ratio of 1:0.4:1. CDHP inhibits DPD 200-fold more potently than does uracil [Shirasaka et al. 1996a, 1996b]. Even after administration of S-1, the primary 5-FU metabolite formed by DPD is observed in significant concentrations in plasma [Kim et al. 2007]. Thus, DPD remains an essential detoxification enzyme of 5-FU, even when its activity is strongly inhibited. The ultimate proof of theory is the occurrence of 18 treatment-related deaths in patients with cancer and herpes zoster given UFT plus the antiviral drug sorivudine [Pharmaceutical Affairs Bureau, 1994]. Subsequent studies in rats showed that a metabolite of sorivudine, (E)-5-(2-bromovinyl)uracil, instantly and irreversibly inactivates DPD by covalent binding, which has been identified as the underlying mechanism of these toxic deaths [Ogura et al. 1998; Okuda et al. 1998]. It is for these arguments that the Summary of Product Characteristics of UFT notes a known DPD deficiency as a contra-indication [Merck Serono, 2011]. The fact that the patients described by Cubero and colleagues did not develop significant toxicity might be due to patient selection, the slightly decreased dose intensity of 90%, or despite their DPYD*2A genotype a DPD enzyme activity within the (lower) range of normal. We are not aware of this, because DPD enzyme activity was not determined in these patients. In summary, we would like to state that standard-dose UFT is not a safe treatment in (partial) DPD-deficient patients. Instead, dose reductions of on average 50% of either capecitabine, 5-FU or UFT with careful monitoring of safety and further dose titration are proposed as the standard of care [Deenen et al. 2011].
- Published
- 2013
38. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study
- Author
-
Henk Boot, Jan H.M. Schellens, Maarten J. Deenen, Jos H. Beijnen, Luc Dewit, and Annemieke Cats
- Subjects
Male ,Cancer Research ,Anal Carcinoma ,medicine.medical_treatment ,Administration, Oral ,Deoxycytidine ,Antineoplastic Combined Chemotherapy Protocols ,Infusions, Intravenous ,Fatigue ,Radiation ,Middle Aged ,Anus Neoplasms ,Combined Modality Therapy ,Oncology ,Lymphatic Metastasis ,Carcinoma, Squamous Cell ,Female ,Fluorouracil ,Radiodermatitis ,medicine.drug ,Adult ,Diarrhea ,medicine.medical_specialty ,Maximum Tolerated Dose ,Mitomycin ,Urology ,Pain ,Capecitabine ,Cytidine Deaminase ,medicine ,Anal cancer ,Humans ,Radiology, Nuclear Medicine and imaging ,Dihydrouracil Dehydrogenase (NADP) ,Aged ,Polymorphism, Genetic ,business.industry ,Mitomycin C ,Dose fractionation ,medicine.disease ,Surgery ,Radiation therapy ,Regimen ,Glutathione S-Transferase pi ,Concomitant ,Feasibility Studies ,Dose Fractionation, Radiation ,Radiotherapy, Intensity-Modulated ,business - Abstract
Purpose Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer. This phase 1, dose-finding study assessed the feasibility and efficacy of simultaneous integrated boost–intensity modulated radiation therapy (SIB-IMRT) with concomitant capecitabine and mitomycin C in locally advanced anal cancer, including pharmacokinetic and pharmacogenetic analyses. Methods and Materials Patients with locally advanced anal carcinoma were treated with SIB-IMRT in 33 daily fractions of 1.8 Gy to the primary tumor and macroscopically involved lymph nodes and 33 fractions of 1.5 Gy electively to the bilateral iliac and inguinal lymph node areas. Patients received a sequential radiation boost dose of 3 × 1.8 Gy on macroscopic residual tumor if this was still present in week 5 of treatment. Mitomycin C 10 mg/m 2 (maximum 15 mg) was administered intravenously on day 1, and capecitabine was given orally in a dose-escalated fashion (500-825 mg/m 2 b.i.d.) on irradiation days, until dose-limiting toxicity emerged in ≥2 of maximally 6 patients. An additional 8 patients were treated at the maximum tolerated dose (MTD). Results A total of 18 patients were included. The MTD of capecitabine was determined to be 825 mg/m 2 b.i.d. The predominant acute grade ≥3 toxicities included radiation dermatitis (50%), fatigue (22%), and pain (6%). Fifteen patients (83% [95%-CI: 66%-101%]) achieved a complete response, and 3 (17%) patients a partial response. With a median follow-up of 28 months, none of the complete responders, and 2 partial responders had relapsed. Conclusions SIB-IMRT with concomitant single dose mitomycin C and capecitabine 825 mg/m 2 b.i.d. on irradiation days resulted in an acceptable safety profile, and proved to be a tolerable and effective treatment regimen for locally advanced anal cancer.
- Published
- 2012
39. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry
- Author
-
Jos H. Beijnen, Maarten J. Deenen, Hilde Rosing, Michel J.X. Hillebrand, and Jan H.M. Schellens
- Subjects
Analyte ,Bioanalysis ,Electrospray ,Clinical Biochemistry ,Tandem mass spectrometry ,Biochemistry ,Deoxycytidine ,Sensitivity and Specificity ,Mass Spectrometry ,Analytical Chemistry ,Capecitabine ,Drug Stability ,Tandem Mass Spectrometry ,medicine ,Protein precipitation ,Humans ,Prodrugs ,Chromatography, High Pressure Liquid ,Chromatography ,Chemistry ,Hydrophilic interaction chromatography ,Reproducibility of Results ,Cell Biology ,General Medicine ,Reversed-phase chromatography ,Linear Models ,Fluorouracil ,medicine.drug - Abstract
Capecitabine is the oral prodrug of the anticancer drug 5-fluorouracil (5-FU). The purpose of this study was to quantify capecitabine and its metabolites including 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5-FU, dihydro-5-fluorouracil (FUH(2)), α-fluoro-ureidopropionic acid (FUPA) and fluoro-β-alanine (FBAL) in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. To this end two individual assays were developed: one for the simultaneous quantification of capecitabine, 5'-dFCR and 5'-dFUR using reversed phase chromatography and gradient elution, and one assay for 5-FU, FUH(2), FUPA and FBAL using hydrophilic interaction chromatography and isocratic elution. Both assays were fully validated according to current FDA guidelines. Total run time for the capecitabine assay was 9.0min, and of the 5-FU assay 5.0min. Analyte extraction was performed by protein precipitation. Stable labeled isotopes for each of the analytes were used as internal standards. The linear ranges of the analytes were 50-6000ng/mL for the capecitabine assay and 50-5000ng/mL for the 5-FU assay. Validation results demonstrate that capecitabine and its metabolites can be rapidly, accurately, precisely and robustly quantified in human plasma with the presented methods. Both assays are currently in extensive use in support of pharmacokinetic studies in patients treated with capecitabine or 5-FU.
- Published
- 2012
40. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine
- Author
-
Annemieke Cats, Jan H.M. Schellens, Henk Boot, Wim E. Terpstra, and Maarten J. Deenen
- Subjects
Antimetabolites, Antineoplastic ,Dihydropyrimidine Dehydrogenase Deficiency ,Colorectal cancer ,medicine.medical_treatment ,Pharmacology ,Tegafur ,Deoxycytidine ,Capecitabine ,chemistry.chemical_compound ,Pharmacokinetics ,Internal Medicine ,medicine ,Humans ,Prodrugs ,Dihydrouracil Dehydrogenase (NADP) ,Chemotherapy ,business.industry ,Rectal Neoplasms ,Uracil ,General Medicine ,medicine.disease ,chemistry ,Fluorouracil ,Toxicity ,Female ,business ,medicine.drug - Published
- 2010
41. Screening for polymorphisms in the PXR gene in a Dutch population
- Author
-
Tessa M. Bosch, Jos H. Beijnen, Roelof Pruntel, Jan H.M. Schellens, Maarten J. Deenen, Paul H.M. Smits, and Irma Meijerman
- Subjects
Male ,Receptors, Steroid ,Population ,Single-nucleotide polymorphism ,Biology ,digestive system ,Polymorphism, Single Nucleotide ,Cytochrome P-450 Enzyme System ,Gene Frequency ,Genotype ,SNP ,Cytochrome P-450 CYP3A ,Humans ,Pharmacology (medical) ,Genetic Testing ,Allele ,education ,Gene ,Netherlands ,Pharmacology ,Genetics ,education.field_of_study ,Pregnane X Receptor ,General Medicine ,Exons ,Molecular biology ,digestive system diseases ,Introns ,genomic DNA ,Nuclear receptor ,Pharmacogenetics ,Female - Abstract
Cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of over 50% of all drugs currently in use. However, CYP3A4 expression shows a large inter-individual variation that cannot only be explained by genetic polymorphisms identified in this gene. The pregnane X receptor (PXR) has been identified as a transcriptional regulator of CYP3A4. Single nucleotide polymorphisms (SNPs) in the PXR gene could influence PXR activity and thereby CYP3A4 expression. This study was therefore aimed at determining the frequencies of known SNPs and detecting yet unknown SNPs in the PXR gene in a Dutch population. Genomic DNA was isolated from blood samples obtained from 100 healthy volunteers and subjected to PCR amplification, followed by DNA sequencing. The population, of which the ethnicity was 93% Caucasian, consisted of 79 female individuals and 21 males. A total of 24 SNPs were found in the PXR gene, eight of which are previously unknown. The allelic frequencies found in this population varied from 0.5 to 73%. Most of the previously detected SNPs were located in introns. One new SNP, T8555G in exon 8, causes an amino acid change of C379G and is located in the Ligand Binding Domain of PXR. Several SNPs were detected in the PXR gene, one of which is located in the ligand binding domain (LBD). These SNPs may influence PXR-mediated CYP3A4 induction.
- Published
- 2005
42. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines
- Author
-
Tessa M. Bosch, Esther F. A. Brandon, Jos H. Beijnen, Maarten J. Deenen, Joyce B.M. van Meerveld, Irma Meijerman, Jan H.M. Schellens, Monique Bijl, Everdina van der Wal, and Rianne Levink
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cell ,ATP-binding cassette transporter ,Biology ,Toxicology ,Cytochrome P-450 Enzyme System ,In vivo ,Transferases ,Internal medicine ,Cell Line, Tumor ,medicine ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Biotransformation ,Pharmacology ,chemistry.chemical_classification ,Ovarian Neoplasms ,Polymorphism, Genetic ,Carcinoma ,Liver Neoplasms ,Cytochrome P450 ,Membrane Transport Proteins ,Biological Transport ,In vitro ,Endocrinology ,Enzyme ,medicine.anatomical_structure ,Biochemistry ,chemistry ,Caco-2 ,Pharmacogenetics ,Colonic Neoplasms ,Inactivation, Metabolic ,biology.protein ,Female ,Caco-2 Cells ,Drug Screening Assays, Antitumor ,Drug metabolism - Abstract
Human cell lines are often used for in vitro biotransformation and transport studies of drugs. In vivo, genetic polymorphisms have been identified in drug-metabolizing enzymes and ABC-drug transporters leading to altered enzyme activity, or a change in the inducibility of these enzymes. These genetic polymorphisms could also influence the outcome of studies using human cell lines. Therefore, the aim of our study was to pharmacogenotype four cell lines frequently used in drug metabolism and transport studies, HepG2, IGROV-1, CaCo-2 and LS180, for genetic polymorphisms in biotransformation enzymes and drug transporters. The results indicate that, despite the presence of some genetic polymorphisms, no real effects influencing the activity of metabolizing enzymes or drug transporters in the investigated cell lines are expected. However, this characterization will be an aid in the interpretation of the results of biotransformation and transport studies using these in vitro cell models.
- Published
- 2005
43. Is Fluorouracil-Induced Severe Toxicity in DPYD*2A Individuals Related to Sex or to Treatment Regimen?
- Author
-
Jan H.M. Schellens, Maarten J. Deenen, and Jos H. Beijnen
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Treatment regimen ,business.industry ,Pharmacology ,Regimen ,Bolus (medicine) ,Fluorouracil ,Internal medicine ,Toxicity ,medicine ,DPYD ,business ,Severe toxicity ,Pharmacogenetics ,medicine.drug - Abstract
TO THEEDITOR:We very much appreciate the prospective manner of the study conducted by Schwab et al, 1 in which fluorouracil (FU) treatment-related toxicity was correlated with genetic and nongenetic factors in patients treated with FU monotherapy-based regimens. The study elegantly illustrated the complex and diverse clinical pictureallelicvariantsmayinduce,andservesasamodelforprospective pharmacogenetic validation studies. However, we propose that theauthorstakeanotherpotentiallycrucialparameterintheiranalysis into account that might lead to a different interpretation of the study results. Toxicity to FU depends on the type of treatment regimen, also illustrated by Schwab et al, with the bolus Mayo regimen resulting in the highest overall grade 3/4 toxicity rate. Based on the study results presented,webelievethatdevelopmentofseveretoxicityinDPYD*2A heterozygotes is determined by the treatment regimen and not by mode of administration nor by sex. Schwabetalobservedthatonlysixoutof13DPYD*2Aheterozy
- Published
- 2008
44. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy
- Author
-
R. Bakker, J.H.M. Schellens, Johan L. Severens, J. H. Beijnen, Paul H.M. Smits, M. K. Sechterberger, Annemieke Cats, Maarten J. Deenen, Caroline M.P.W. Mandigers, and Marcel Soesan
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cost effectiveness ,food and beverages ,Detoxification enzymes ,Pharmacokinetics ,Internal medicine ,Toxicity ,medicine ,DPYD ,business ,Genotyping - Abstract
3606 Background: Fluoropyrimidines, although generally well tolerated, can induce life-threatening toxicity. The major known cause of intolerance is deficiency of the detoxifying enzyme dihydropyri...
- Published
- 2011
45. DPYD single nucleotide polymorphisms (SNPs) and haplotypes in patients (pts) with metastatic colorectal cancer and toxicity of capecitabine
- Author
-
Andrew D. Vincent, C.J.A. Punt, Artur M. Burylo, H-J Guchelaar, Annemieke Cats, J.H.M. Schellens, Jolien Tol, Maarten J. Deenen, A. G. E. M. de Boer, and J. H. Beijnen
- Subjects
Cancer Research ,Colorectal cancer ,business.industry ,Haplotype ,Single-nucleotide polymorphism ,Prodrug ,medicine.disease ,Capecitabine ,Oncology ,Dihydropyrimidine dehydrogenase ,medicine ,Cancer research ,SNP ,DPYD ,business ,medicine.drug - Abstract
3099 Background: Capecitabine is the oral prodrug of 5-FU, which is inactivated for 85% by dihydropyrimidine dehydrogenase (DPD, DPYD). The aim of this study was to determine the effect of DPYD SNP...
- Published
- 2010
46. Phase I and pharmacokinetic study of everolimus and capecitabine in patients with solid tumors
- Author
-
D.J. Richel, Heinz-Josef Klümpen, J.H.M. Schellens, Johanna W. Wilmink, J. H. Beijnen, R. Sparidans, and Maarten J. Deenen
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Everolimus ,business.industry ,Cancer ,Discovery and development of mTOR inhibitors ,medicine.disease ,Capecitabine ,Pharmacokinetics ,Internal medicine ,medicine ,In patient ,business ,PI3K/AKT/mTOR pathway ,medicine.drug - Abstract
2557 Background: Results form (pre)clinical studies suggest that mTOR inhibitors are promising drugs for the treatment of various types of cancer. Everolimus seems the most attractive mTOR inhibito...
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.